Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
1 clinical trials · Condition
◉ Watch Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
| Record | Firm | Date |
|---|---|---|
| A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) (NCT05568225) | Forma Therapeutics, Inc. | 2022-11-15 |
Track Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R automatically
Every clearance here is in the API, with alerts when new ones post.